Press Releases

All Releases
May 06, 2014
AngioDynamics to Present at Upcoming Investor Conferences
ALBANY, N.Y. , May 6, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today the company will present at the following investor conferences in
Apr 09, 2014
AngioDynamics Reports Fiscal 2014 Third Quarter Financial Results
Net sales increase 8% over prior year to $88.2 million GAAP income per share of $0.14 ; Non-GAAP adjusted net income, excluding amortization, of $0.16 per share Adjusted EBITDA of $14.6 million Company's revenue guidance to $351 million - $355 million for FY14; Adjusted EPS, excluding amortization,
Mar 25, 2014
AngioDynamics to Report Fiscal 2014 Third Quarter Financial Results
ALBANY, N.Y. , March 25, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 third quarter financial results
Mar 20, 2014
AngioDynamics Awarded $74.9 Million in Case Against biolitec AG
ALBANY, N.Y. , March 20, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced a recent court action in its legal case against biolitec AG.
Mar 11, 2014
AngioDynamics Receives Expanded FDA Clearance for AngioVac
ALBANY, N.Y. , March 11, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded
Mar 03, 2014
AngioDynamics to Present at the Barclays Global Healthcare Conference
ALBANY, N.Y. , March 3, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,
Jan 09, 2014
AngioDynamics Reports Fiscal 2014 Second Quarter Financial Results
Net sales of $88.6 million GAAP income per share at break-even; Non-GAAP adjusted net income, excluding amortization, of $0.14 per share Adjusted EBITDA of $12.7 million Operating cash flow of $8.2 million Company raises low end of revenue guidance to $349-$353 million for FY14; reiterates adjusted
Dec 12, 2013
AngioDynamics to Report Fiscal 2014 Second Quarter Financial Results
ALBANY, N.Y. , Dec. 12, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 second quarter financial results
Dec 11, 2013
AngioDynamics Appoints John Soto Chief Commercial Officer
ALBANY, N.Y. , Dec. 11, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of John Soto as Chief Commercial Officer, a
Nov 04, 2013
AngioDynamics to Present at Upcoming Investor Conferences
ALBANY, N.Y. , Nov. 4, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,
Oct 10, 2013
AngioDynamics Reports Fiscal 2014 First Quarter Financial Results
Net sales of $83.6 million GAAP net loss of $0.01 per share; Non-GAAP adjusted net income of $0.04 per share; Non-GAAP adjusted net income excluding amortization of $0.12 per share Adjusted EBITDA of $11.3 million Operating cash flow of $7.3 million versus prior year $5.6 million cash use Company
Displaying 121 - 140 of 637